Narsoplimab is a medicine for a rare problem after a stem cell transplant where tiny blood clots damage small blood vessels. It is given as an infusion into a vein. It works by blocking part of the immune system that can injure the lining of blood vessels.
Every report comes from a Lived member, sent anonymously.
Have you tried Yartemlea (Narsoplimab) for Thrombotic Microangiopathies?
Narsoplimab, sold as Yartemlea, is a prescription antibody medicine for transplant-associated thrombotic microangiopathy (TA-TMA), a serious complication that can follow a stem cell transplant, the type of transplant sometimes called a bone marrow transplant. In TA-TMA, the inner lining of the body's smallest blood vessels is damaged. Tiny clots form, platelets get used up, red blood cells are broken apart as they squeeze through, and organs that depend on fine blood vessels, especially the kidneys, can be harmed. It is approved in the US for adults and children 2 years and older with TA-TMA, and in December 2025 it became the first medicine approved specifically for this condition. It is used by transplant teams in hospital or infusion settings, usually alongside other steps such as adjusting transplant medicines that can contribute to blood vessel injury. It is not approved for other clotting disorders of small vessels, such as thrombotic thrombocytopenic purpura or atypical hemolytic uremic syndrome.
The complement system is part of the immune system. It is a chain of proteins in the blood that switches on to attack germs, but after a transplant it can turn against the body's own blood vessel lining. One of the routes that sets this chain off is called the lectin pathway, and an enzyme named MASP-2 drives it. Narsoplimab is a lab-made antibody that attaches to MASP-2 and blocks it. That shuts down the lectin pathway while leaving the other two complement routes working. The aim is to stop the ongoing injury to small blood vessels so platelet counts can recover, red cell breakdown can settle and organ function can improve. Researchers believe this is how it helps in TA-TMA, but the full chain from blocking MASP-2 to clinical recovery is not completely mapped out.
Narsoplimab is given by a nurse as an infusion into a vein over about 30 minutes, once a week. People who weigh 50 kg (about 110 pounds) or more receive a fixed dose; children and smaller adults receive a dose calculated from body weight. If signs of TA-TMA are not improving enough, the care team may increase infusions to twice a week. Because it is prepared and given by the transplant or infusion team, there is nothing to measure out at home. If a scheduled infusion is missed, it is usually given as soon as possible, and then the regular schedule resumes.
In the main study, people receiving narsoplimab often had diarrhea, nausea, vomiting, fever, tiredness, bleeding, low potassium and low counts of neutrophils, the white blood cells that fight bacteria. Many of these problems are also common after a stem cell transplant itself, so it can be hard to tell which are caused by the medicine. The most important risk is serious infection. Because narsoplimab blocks part of the immune defense, serious and sometimes life-threatening infections, including bloodstream infections (sepsis), pneumonia, and viral and fungal infections, have occurred during treatment. Contact the transplant team right away about a fever, chills, a new cough or shortness of breath, or feeling suddenly much more unwell, and follow any fever instructions the transplant center has given.
The label lists no specific drug interactions and no situations in which narsoplimab must never be used. The main caution is giving it to someone who already has an active infection: the team can still use it but will watch closely and treat any infection promptly. Make sure every clinician involved knows narsoplimab is part of the treatment plan, since it adds to the infection risk already present after transplant. There is too little information to know whether narsoplimab affects a pregnancy. Like other antibody medicines, it is expected to cross the placenta, mainly late in pregnancy, so an exposed newborn may still have it in the blood. There is also no information on whether it passes into human breast milk. Anyone who is pregnant, could become pregnant or is breastfeeding should raise this with the transplant team.
Treatment is followed with regular blood and urine tests. The team watches platelet counts, LDH (lactate dehydrogenase, an enzyme released when red blood cells and tissues are damaged), signs of red cell breakdown, and kidney function. Improvement in these numbers, and less need for platelet or red blood cell transfusions, shows that the medicine is working. In the main study, treatment typically lasted about 8 weeks, though some people needed it for longer. The evidence comes from a study of 28 adults without a comparison group and from an expanded access program that included children. About 6 in 10 adults in the study had a meaningful response in their blood counts and organ function, and roughly 3 in 4 were alive 100 days after diagnosis. A later analysis found lower death rates than in a similar group of transplant patients who did not receive it, but that was not a randomized comparison. TA-TMA often occurs alongside other serious transplant problems such as graft-versus-host disease and infection, which strongly affect how someone does, so outcomes vary widely and the medicine is one part of a broader plan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Yartemlea (Narsoplimab), what you've noticed, or ask the community a question.